V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004023 | 310001702 | 1.68 | 13.2 | Neo-adjuvant (N) | 2015-10-03 | 2015-10-07 | Cisplatin +Fluorouracil (3 wk) | N | N | 310019073 | BEXAROTENE |
| 310004024 | 310001703 | null | null | Adjuvant (A) | 2016-05-08 | 2016-05-09 | Gemcitabine weekly | 2 | N | 310019076 | GEMCITABINE |
| 310004025 | 310001703 | 1.86 | 114.2 | null | 2018-04-20 | 2018-05-19 | Hydroxycarbamide | Y | N | 310019076 | HYDROXYCARBAMIDE |
| 310004026 | 310001703 | 1.72 | 63 | Disease modification (D) | 2016-11-29 | 2016-12-03 | Gemcitabine day 1&8 | N | N | 310019076 | GEMCITABINE |
| 310004027 | 310001703 | null | null | Palliative (P) | 2013-02-16 | 2013-02-23 | IPILIMUMAB + NIVOLUMAB | N | Y | 310019076 | BEXAROTENE |
| 310004028 | 310001703 | 1.56 | 56.7 | Palliative (P) | null | 2017-03-18 | Capecitabine + Cisplatin | 2 | N | 310019076 | OXALIPLATIN + MDG |
| 310004029 | 310001704 | 1.72 | null | Palliative (P) | 2016-10-07 | 2016-10-15 | Capecitabine + Cisplatin | N | N | 310019087 | OXALIPLATIN + MDG |
| 310004031 | 310006750 | null | 81.8 | Adjuvant (A) | 2014-06-21 | 2014-07-07 | Liposomal Doxorubicin 40mg/m2 | N | N | 310019091 | CISPLATIN + ETOPOSIDE |
| 310004032 | 310001706 | 1.51 | null | Curative (C) | 2016-05-10 | 2016-05-11 | Liposomal Doxorubicin 40mg/m2 | N | N | 310019093 | GEMCITABINE + PACLITAXEL |
| 310004033 | 310006751 | null | 92.3 | Palliative (P) | null | 2014-09-12 | BEVACIZUMAB + CARBO + PACLITAXEL | null | null | 310019095 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004034 | 310006751 | 1.67 | null | Curative (C) | 2016-04-28 | 2016-04-28 | ECX | 2 | N | 310019095 | CAPECITABINE + OXALIPLATIN |
| 310004035 | 310006751 | null | 77.5 | Adjuvant (A) | 2017-06-03 | 2017-06-07 | Rituximab | 2 | N | 310019095 | RITUXIMAB |
| 310004036 | 310001707 | 1.62 | 51.7 | Adjuvant (A) | 2016-04-08 | 2016-04-15 | Imatinib 400mg | N | N | 310019100 | CISPLATIN + ETOPOSIDE |
| 310004041 | 310001708 | 1.67 | 67 | Palliative (P) | 2012-04-17 | 2012-04-17 | IPILIMUMAB + NIVOLUMAB | N | N | 310019115 | BCG |
| 310004042 | 310006753 | 1.75 | 72 | Palliative (P) | 2015-11-29 | 2015-11-29 | CISPLATIN + DOCETAXEL + FLUOROURACIL | Y | N | 310019116 | GEMCITABINE + PACLITAXEL |
| 310004043 | 310001709 | 1.73 | 129 | null | 2014-03-11 | 2014-03-17 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 310019117 | PACLITAXEL |
| 310004044 | 310001710 | 1.47 | 59 | Curative (C) | 2017-10-12 | 2017-11-13 | CHOEP - 21 days | N | N | 310019118 | CHOEP |
| 310004045 | 310001711 | null | null | Palliative (P) | 2013-01-18 | 2013-01-18 | EOX | null | null | 310019119 | BCG |
| 310004046 | 310001712 | 1.77 | 82 | Palliative (P) | 2015-10-16 | 2015-10-16 | IPILIMUMAB + NIVOLUMAB | 2 | N | 310019122 | IPILIMUMAB + NIVOLUMAB |
| 310004048 | 310001714 | null | 62.4 | Neo-adjuvant (N) | 2014-03-23 | 2014-04-10 | Vemurafenib | 02 | N | 310019126 | OXALIPLATIN + MDG |
| 310004049 | 310001715 | 1.62 | null | Neo-adjuvant (N) | 2016-08-28 | 2016-08-29 | BEVACIZUMAB + CARBO + PACLITAXEL | 1 | N | 310019127 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004050 | 310001716 | 1.78 | 71.9 | Palliative (P) | 2015-05-01 | 2015-05-21 | Vemurafenib | N | N | 310019129 | MITOMYCIN INTRAVESICULAR |
| 310004051 | 310001717 | 1.86 | 93.4 | Palliative (P) | 2015-06-18 | 2015-06-19 | CHOEP - 21 days | N | N | 310019130 | CAPECITABINE |
| 310004052 | 310001718 | 1.72 | null | Curative (C) | 2017-08-30 | 2017-09-14 | CHOEP - 21 days | N | N | 310019131 | CHOEP |
| 310004053 | 310001719 | 1.8 | 0 | Palliative (P) | null | 2015-12-28 | CISPLATIN + FLUOROURACIL | N | N | 310019133 | EOX |
| 310004054 | 310001720 | 1.75 | 94.8 | Curative (C) | null | 2014-07-03 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 2 | N | 310019134 | NOT MATCHED |
| 310004055 | 310006754 | 1.58 | 73.6 | Palliative (P) | 2015-06-21 | 2015-06-21 | GEM-P | 02 | N | 310019136 | OXALIPLATIN + MDG |
| 310004056 | 310009136 | 1.67 | 69.2 | Disease modification (D) | 2017-05-05 | 2017-05-09 | Imatinib 400mg | N | N | 310019138 | VEMURAFENIB |
| 310004057 | 310009136 | 1.86 | 85.9 | Palliative (P) | 2013-08-09 | 2013-08-11 | Oxaliplatin + Modified de Gramont | N | N | 310019138 | CISPLATIN + ETOPOSIDE |
| 310004058 | 310009136 | null | 84.7 | Palliative (P) | 2013-05-11 | 2013-05-14 | ECX | N | N | 310019138 | ECX |
| 310004059 | 310001721 | 1.67 | 68.7 | Adjuvant (A) | 2014-09-12 | 2014-09-17 | ECX | N | N | 310019143 | ECX |
| 310004060 | 310001722 | 1.61 | 66.5 | null | null | 2015-09-20 | CHOEP | N | N | 310019145 | CHOEP |
| 310004061 | 310001723 | null | 68.9 | Palliative (P) | 2012-08-24 | 2014-02-14 | Bexarotene | 02 | N | 310019146 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004062 | 310001724 | 1.75 | 95 | null | null | 2017-12-15 | ICON8 TRIAL | 02 | N | 310019149 | IMATINIB |
| 310004063 | 310001725 | 1.8 | 0 | Curative (C) | null | 2017-02-14 | Liposomal Doxorubicin (Caelyx) | 2 | N | 310019150 | DACARBAZINE |
| 310004064 | 310001726 | 1.58 | 99.8 | Palliative (P) | 2013-12-30 | 2015-04-06 | ECX | N | N | 310019151 | ECX |
| 310004065 | 310001727 | null | 73.9 | Palliative (P) | 2017-03-29 | 2017-04-09 | Bexarotene | N | N | 310019153 | GEMCITABINE + PACLITAXEL |
| 310004066 | 310006755 | 1.6 | 64.4 | Curative (C) | 2015-10-09 | 2015-10-12 | CHOEP - 21 days | null | null | 310019155 | CHOEP |
| 310004067 | 310009137 | 1.72 | 82.4 | Palliative (P) | 2015-04-03 | 2015-04-11 | Imatinib 400mg | 2 | N | 310019156 | CISPLATIN + FLUOROURACIL |
| 310004068 | 310009137 | 1.69 | null | Palliative (P) | 2017-04-16 | 2017-04-22 | Mitomycin Intravesical | 01 | N | 310019156 | EOX |
| 310004069 | 310011072 | 1.51 | 52.8 | Disease modification (D) | 2013-09-01 | 2013-09-02 | Cisplatin +Fluorouracil (3 wk) | 02 | null | 310019163 | CAPECITABINE + OXALIPLATIN |
| 310004070 | 310011072 | 1.75 | 71 | Palliative (P) | 2013-09-22 | 2013-09-22 | CISPLATIN + FLUOROURACIL | 02 | null | 310019163 | LIPOSOMAL DOXORUBICIN |
| 310004071 | 310001728 | null | 57.5 | Curative (C) | 2015-01-08 | 2015-01-08 | CHOEP - 21 days | N | N | 310019169 | CHOEP |
| 310004072 | 310001729 | 1.46 | 72.1 | Curative (C) | 2016-05-16 | 2016-05-16 | Rituximab | N | N | 310019172 | EOX |
| 310004074 | 310001730 | 1.56 | 94 | null | 2016-03-25 | 2016-03-25 | Vemurafenib | 01 | null | 310019174 | BEXAROTENE |
| 310004075 | 310001731 | null | 47.6 | null | null | 2015-07-27 | Mitomycin Intravesical | 02 | N | 310019175 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004076 | 310001732 | null | 98.4 | Curative (C) | 2014-04-30 | 2014-08-13 | Bexarotene | N | N | 310019176 | CAPECITABINE |
| 310004077 | 310001733 | 1.9 | 68 | null | null | 2016-10-14 | NB HRNBL-1 Isotretinoin | null | null | 310019177 | NOT MATCHED |
| 310004078 | 310001734 | 1.62 | 64 | Palliative (P) | null | 2014-10-02 | ECX | N | N | 310019178 | ECX |
| 310004079 | 310001734 | 1.83 | 68 | Neo-adjuvant (N) | 2015-05-30 | 2015-05-31 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 310019178 | BEVACIZUMAB + CARBO + PACLITAXEL |